The FDA has approved Rapiblyk, a new drug to treat irregular heartbeats in critically ill hospitalized patients with severe supraventricular tachycardia (SVT), including atrial fibrillation and atrial ...
Methods: A total of 28 children with atrial tachycardia (including focal atrial tachycardia and atrial flutter) who underwent atrial radiofrequency ablation at the Children's Hospital Affiliated to ...
“Rapiblyk TM approval in the US represents an important milestone for patients experiencing supraventricular tachycardia, including atrial fibrillation and atrial flutter, who need rapid and ...
Atrial flutter is often definitively treated with cardiac ablation. These arrhythmias involve abnormalities in the heart's conduction system, such as an "accessory pathway" that allows the electrical ...
We report the history of a full-term newborn. Antenatal echocardiography had diagnosed an atrial flutter. Delivery was carried out by caesarean section. In the check up, the newborn had a heart murmur ...
RESULTS The incidence of in-hospital atrial fibrillation or flutter was 7.8%. Atrial fibrillation was associated with indicators ... and with some adverse clinical events (reinfarction, sustained ...
Two patients suffered from paroxysmal atrial fibrillation. Two patients were complicated with atrioventricular nodal reentrant tachycardia. Three patients were complicated with left accessory ...
Attruby Approved for Cardiomyopathy of Transthyretin-Mediated Amyloidosis Rapiblyk (landiolol) Beta-1 adrenergic receptor blocker For the short-term reduction of ventricular rate in adults with ...
Atrial fibrillation is the most common arrhythmic disorder and is even more prevalent among the elderly. Due to their prevalence, it is imperative for the clinician to be informed about these ...